Scarica l'app Stockscreener
1,142.85
0.61%
-7.00
Dopo l'orario di chiusura:
1144.00
1.15
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,149.85
Aprire:
$1153.82
Volume 24 ore:
2.04M
Relative Volume:
0.82
Capitalizzazione di mercato:
$1.02T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
41.14
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
-3.43%
1M Prestazione:
-1.49%
6M Prestazione:
+22.15%
1 anno Prestazione:
+39.40%
Intervallo 1D:
$1,136.66
$1,164.92
Intervallo di 1 settimana:
$1,136.66
$1,215.00
Portata 52W:
$783.85
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly stock after-hours at EUR 1,028.40: plus 0.07 percent versus prior close - AD HOC NEWS
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO - The Economic Times
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market - Barron's
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal - AOL.com
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk - Benzinga
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says - marketscreener.com
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Analyst recommendations: Alphabet, Amazon, Micron, Tesla, Eli Lilly… - marketscreener.com
BMO reiterates Eli Lilly stock Outperform on TRIUMPH-2 data By Investing.com - Investing.com UK
Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent - AD HOC NEWS
Why Is Eli Lilly (NYSE:LLY) Suddenly a Must-Watch Healthcare Stocks Stock Today? - Kalkine Media
Eli Lilly's Foundayo Shows Promising Results in Reducing Diabetes and Cardiovascular Risks (LLY) - GuruFocus
Eli Lilly's Foundayo Shows Major Diabetes Risk Reduction; LLY St - GuruFocus
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease - PR Newswire
Eli Lilly stock pre-market at EUR 1,025.00: minus 0.26 percent - AD HOC NEWS
Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential for LLY - GuruFocus
Eli Lilly Loses Full Fed. Circ. Bid To Nix Teva's $177M IP Win - Law360
Lilly combo drug cuts weight up to 23% in trial - Briefs Finance
Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr - GuruFocus
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study - PR Newswire
Experimental Lilly combination drug tops Zepbound in weight-loss trial - reuters.com
Missed Out On The Eli Lilly & Novo Nordisk GLP-1 Boom? These 7 Stocks Could Benefit Next! - Stocks Down Under
Doctors condemn big pharma's move to dispense GLP-1s to your door - ABC News & Headlines – Australian Broadcasting Corporation
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds - USA Today
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks - Benzinga
Eli Lilly's EloraTZP Shows Promising Weight Loss Results in Mid-Stage Trial (LLY) - GuruFocus
Eli Lilly unveils compelling Phase 2b results for its EloraTZP combination - marketscreener.com
Eli Lilly (LLY) Reports Promising Phase 2b Results for EloraTZP in Obesity and Type 2 Diabetes - GuruFocus
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial - statnews.com
Eli Lilly (LLY) Reports Promising Phase 2b Trial Results for Elo - GuruFocus
Eloralintide: Eli Lilly's New Obesity Treatment Shows Promising Results - GuruFocus
Eli Lilly stock rises on striking 23% weight loss in drug combo trial - Investing.com
What's Behind Eli Lilly's (NYSE:LLY) Big Moment in Healthcare Stocks Today? - Kalkine Media
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli - Benzinga
Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study - Bloomberg.com
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com
Eli Lilly's Ebglyss Shows Strong Phase 3b Results for Atopic Der - GuruFocus
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Is Eli Lilly and Co (LLY) a Bargain After 0.0% Drop? GF Value Sa - GuruFocus
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly (LLY) Reports Strong TRIUMPH-2 Trial Results for Retat - GuruFocus
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results - yahoo.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data - yahoo.com
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy - Yahoo Finance
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis - reuters.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):